8/10/2010

Tissue Regenix said it has obtained European CE Marking for its first product, the dCELL vascular patch. The technology works by removing cells in humans and animals, creating a scaffold where new body parts can grow. The method would eliminate the need for anti-rejection drugs.

Related Summaries